Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized contr...
Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial
About this item
Full title
Author / Creator
Adabag, A. Selcuk, MD, MS , Mithani, Salima, MD , Al Aloul, Basel, MD , Collins, Dorothea, ScD , Bertog, Stefan, MD , Bloomfield, Hanna E., MD, MPH , for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
Publisher
New York, NY: Mosby, Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Mosby, Inc
Subjects
More information
Scope and Contents
Contents
Background Peroxisome proliferator–activated receptor α (PPARα) activators reduce inflammation and oxidative stress. Inflammation plays an important role in the initiation and maintenance of atrial fibrillation (AF). It has been suggested that PPARα activators may have antiarrhythmic properties, but no clinical data exist. The objective of this stu...
Alternative Titles
Full title
Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial
Authors, Artists and Contributors
Author / Creator
Mithani, Salima, MD
Al Aloul, Basel, MD
Collins, Dorothea, ScD
Bertog, Stefan, MD
Bloomfield, Hanna E., MD, MPH
for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_67138415
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_67138415
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2009.02.015
